The Ipsen Group Publishes Its 2012 Registration Document

Regulatory News :

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today that its 2012 Registration Document has been filed with the French "Autorité des Marchés Financiers (AMF)” on 26 March 2013 and registered under the number D.13-0219.

The document is available on the Company’s website: www.ipsen.com and on the AMF’s website: www.amf-france.org. Copies are also available at Ipsen’s headquarters – 65 quai Georges Gorse, 92650 Boulogne-Billancourt cedex – France.

The following documents are incorporated into the 2012 Registration Document:

• The Annual Financial Report;
• The Chairman’s Report on the preparation and organisation of the works of the Board of Directors and internal control procedures and risk management procedures and the corresponding Statutory Auditor’s report;
• The information relating to the fees paid to the Statutory Auditors.

About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé” ("SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.